BMS-986165

ApprovedRecruiting

0 views this week 0 watching⚡ Active

Interest: 50/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Systemic Lupus Erythematosus (SLE)

Conditions

Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE)

Trial Timeline

Feb 27, 2026 → Dec 1, 2026

NCT ID

NCT06875960

About BMS-986165

BMS-986165 is a approved stage product being developed by Bristol Myers Squibb for Systemic Lupus Erythematosus (SLE). The current trial status is recruiting. This product is registered under clinical trial identifier NCT06875960. Target conditions include Systemic Lupus Erythematosus (SLE), Discoid and/or Subacute Cutaneous Lupus Erythematosus (DLE/SCLE).

What happened to similar drugs?

9 of 20 similar drugs in Systemic Lupus Erythematosus (SLE) were approved

Approved (9) Terminated (4) Active (8)

✅Baricitinib + CyclophosphamideEli LillyApproved

✅Rosuvastatin + SimvastatinAstraZenecaApproved

✅AnifrolumabAstraZenecaApproved

✅EfalizumabMerckApproved

✅AmbrisentanGilead SciencesApproved

✅versus hydroxychloroquineSanofiApproved

✅Belimumab plus Early Vaccination + Belimumab plus Late VaccinationGSK plcApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06875960	Approved	Recruiting	Feb 27, 2026	Dec 1, 2026	Systemic Lupus Erythematosus (SLE)
NCT04613518	Phase 2	Completed	Mar 15, 2021	Nov 29, 2023	Colitis, Ulcerative
NCT04167462	Phase 3	Completed	Nov 25, 2019	Jan 7, 2022	Psoriasis
NCT03934216	Phase 2	Completed	Jul 1, 2019	Apr 4, 2023	Ulcerative Colitis
NCT03924427	Phase 3	Completed	Apr 10, 2019	Mar 24, 2021	Psoriasis
NCT03890770	Phase 1	Completed	Apr 4, 2019	Feb 13, 2020	Renal Impairment
NCT03956953	Phase 1	Completed	Apr 4, 2019	Sep 25, 2019	Autoimmune Diseases
NCT03920267	Phase 2	Completed	Mar 26, 2019	Mar 21, 2025	Systemic Lupus Erythematosus
NCT03890809	Phase 1	Completed	Feb 26, 2019	Nov 30, 2019	Liver Dysfunction
NCT03873415	Phase 1	Completed	Jan 25, 2019	May 1, 2019	Psoriasis
NCT03739788	Phase 1	Completed	Dec 5, 2018	Feb 11, 2019	Healthy Participants
NCT03599622	Phase 2	Terminated	Jul 16, 2018	Oct 23, 2023	Granulomatous Colitis
NCT03252587	Phase 2	Completed	Sep 21, 2017	Oct 28, 2021	Systemic Lupus Erythematosus
NCT03004768	Phase 1	Completed	Jan 26, 2017	Feb 27, 2017	Psoriasis

Competing Products

20 competing products in Systemic Lupus Erythematosus (SLE)

See all competitors

Product	Company	Stage	Hype Score
Tabalumab Auto-Injector + Tabalumab Prefilled Syringe	Eli Lilly	Phase 3	32
Baricitinib + Placebo	Eli Lilly	Phase 2	35
MRA(Tocilizumab) + placebo	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
MRA(Tocilizumab)	Chugai Pharmaceutical	Phase 3	40
DS-7011a + Placebo	Daiichi Sankyo	Phase 1	29
DS-7011a + Placebo	Daiichi Sankyo	Phase 1/2	32
Bocidelpar + Placebo	Astellas Pharma	Phase 1	21
Parenteral micafungin application + Other parenteral antifungal drugs	Astellas Pharma	Pre-clinical	26
Micafungin	Astellas Pharma	Phase 2	35
E6742	Eisai	Phase 1/2	32
KHK4827	Kyowa Kirin	Phase 1	29
KHK4827 + Placebo	Kyowa Kirin	Phase 3	40
Baricitinib + Placebo	Eli Lilly	Phase 3	40
Baricitinib + Cyclophosphamide	Eli Lilly	Approved	47
Baricitinib + Placebo	Eli Lilly	Phase 3	32
LY2127399 + Placebo every 2 weeks + Placebo every 4 weeks + Standard of Care	Eli Lilly	Phase 3	40
LY3361237 + Placebo	Eli Lilly	Phase 2	27
LY2127399 + Placebo	Eli Lilly	Phase 3	32
LY3361237 + Placebo	Eli Lilly	Phase 1	29